Oxaliplatin for Injection Anti-tumor Medicine

The main ingredient of this product is oxaliplatin. Its chemical name is: (1R trans) - (1,2-cyclohexanediamine-N, N ') [oxalic acid (2-) - O, O'] platinum, with lactose as the excipient

This product is a white or off white loose block or amorphous solid or powder.

Oxaliplatin for injection is indicated for patients with colorectal cancer metastasis who have failed treatment with fluorouracil. It can be used alone or in combination with fluorouracil.

This product belongs to a new platinum derivative, in which the central platinum atom is surrounded by oxalic acid and 1,2-diaminocyclohexane, forming a trans conformation and a stereoisomer. Like other platinum derivatives, oxaliplatin acts on DNA by generating alkylated complexes, forming intra - and inter chain crosslinks, thereby inhibiting DNA synthesis and replication. Oxaliplatin binds rapidly to DNA, taking up to 15 minutes, while cisplatin binds to DNA in two phases, including a delayed phase after 48 hours. After one hour of administration in the human body, the presence of adducts can be detected by measuring their levels in white blood cells. The DNA synthesis during replication is inhibited, followed by the isolation of NDA and the synthesis of RNA and cellular proteins. Some cell lines resistant to cisplatin are effectively treated with oxaliplatin.

50mg.

Please use under the guidance of a physician.

1.Oxaliplatin should be used under the supervision of a physician with experience in anti-cancer chemotherapy. Especially when combined with drugs with potential neurotoxicity, the neurological safety of oxaliplatin should be closely monitored.

2. Preventive or therapeutic antiemetic medication should be administered.

When blood toxicity occurs (white blood cells<2000/mm³ or platelets<50000/mm³), the next cycle of medication should be postponed until recovery.

4. Blood count and classification should be performed before each treatment course, neurological examination should be performed before the start of each treatment, and regular follow-up should be conducted thereafter.

5. If the patient continues to experience painful sensory abnormalities or/and functional impairments between two treatment courses, the dosage of this product should be reduced by 25%. If the symptoms persist or worsen after adjusting the dosage, the medication should be discontinued.

6. Do not use with alkaline drugs or media, chloride compounds, alkaline preparations, etc., and do not use intravenous injection devices containing aluminum.

Sealed and stored below 25 degrees Celsius.

Hot Tags: oxaliplatin for injection anti-tumor medicine, China oxaliplatin for injection anti-tumor medicine manufacturers, suppliers, quinolones, receptor blocker, Propofol Injection General Anesthetics, Analgin Injection Cisen, Potassium Chloride Injection Electrolyte